SG11201606173TA - Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof - Google Patents
Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereofInfo
- Publication number
- SG11201606173TA SG11201606173TA SG11201606173TA SG11201606173TA SG11201606173TA SG 11201606173T A SG11201606173T A SG 11201606173TA SG 11201606173T A SG11201606173T A SG 11201606173TA SG 11201606173T A SG11201606173T A SG 11201606173TA SG 11201606173T A SG11201606173T A SG 11201606173TA
- Authority
- SG
- Singapore
- Prior art keywords
- salt
- alkyl ether
- enhancing agent
- nerve injury
- ether derivative
- Prior art date
Links
- 208000028389 Nerve injury Diseases 0.000 title 1
- 150000005215 alkyl ethers Chemical class 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000008764 nerve damage Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014017587 | 2014-01-31 | ||
| PCT/JP2015/052617 WO2015115582A1 (en) | 2014-01-31 | 2015-01-30 | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606173TA true SG11201606173TA (en) | 2016-08-30 |
Family
ID=53757150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606173TA SG11201606173TA (en) | 2014-01-31 | 2015-01-30 | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof |
| SG10201907035TA SG10201907035TA (en) | 2014-01-31 | 2015-01-30 | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201907035TA SG10201907035TA (en) | 2014-01-31 | 2015-01-30 | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10039744B2 (en) |
| EP (1) | EP3100725B1 (en) |
| JP (3) | JP5837726B1 (en) |
| KR (1) | KR102346219B1 (en) |
| CN (1) | CN106061478B (en) |
| AU (1) | AU2015211753B2 (en) |
| BR (1) | BR112016017747A2 (en) |
| CA (1) | CA2938184C (en) |
| CY (1) | CY1123154T1 (en) |
| DK (1) | DK3100725T3 (en) |
| ES (1) | ES2792950T3 (en) |
| HK (1) | HK1226298A1 (en) |
| HR (1) | HRP20200796T1 (en) |
| HU (1) | HUE050400T2 (en) |
| IL (1) | IL246925B (en) |
| LT (1) | LT3100725T (en) |
| MX (1) | MX2016009751A (en) |
| MY (1) | MY179290A (en) |
| PH (1) | PH12016501507A1 (en) |
| PL (1) | PL3100725T3 (en) |
| PT (1) | PT3100725T (en) |
| RS (1) | RS60462B1 (en) |
| RU (1) | RU2680247C2 (en) |
| SG (2) | SG11201606173TA (en) |
| SI (1) | SI3100725T1 (en) |
| WO (1) | WO2015115582A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3100725T3 (en) * | 2014-01-31 | 2020-11-16 | Fujifilm Toyama Chemical Co., Ltd. | Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof |
| US11304928B2 (en) | 2015-12-25 | 2022-04-19 | Fujifilm Toyama Chemical Co., Ltd. | Tablet comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof |
| US20190336476A1 (en) * | 2016-12-28 | 2019-11-07 | Fujifilm Toyama Chemical Co., Ltd. | Pharmaceutical composition |
| JP7079209B2 (en) * | 2016-12-28 | 2022-06-01 | 富士フイルム富山化学株式会社 | Pharmaceutical composition and its manufacturing method |
| JP7176957B2 (en) * | 2016-12-28 | 2022-11-22 | 富士フイルム富山化学株式会社 | external composition |
| JP7057286B2 (en) * | 2016-12-28 | 2022-04-19 | 富士フイルム富山化学株式会社 | Pharmaceutical composition |
| SG11201911519UA (en) * | 2017-06-02 | 2020-01-30 | Fujifilm Toyama Chemical Co Ltd | AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN |
| CN116473962A (en) * | 2017-06-02 | 2023-07-25 | 富士胶片富山化学株式会社 | Agent for preventing or treating brain atrophy |
| JP7370859B2 (en) * | 2017-06-02 | 2023-10-30 | 富士フイルム富山化学株式会社 | Tauopathy prevention or treatment agent |
| JP7133547B2 (en) * | 2017-06-02 | 2022-09-08 | 富士フイルム富山化学株式会社 | Preventive or therapeutic agent for spinocerebellar degeneration |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | Agent for preventing or treating alzheimer-type dementia |
| US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO122203B1 (en) * | 2001-10-19 | 2009-02-27 | Toyama Chemical Co., Ltd. | Alkyl ether derivatives and salts thereof |
| US7753054B2 (en) | 2001-11-29 | 2010-07-13 | Japan Science And Technology Agency | Method of constructing spinal injury model monkey and utilization thereof |
| EP2389937B1 (en) * | 2002-06-14 | 2018-08-15 | Toyama Chemical Co., Ltd. | Medicinal composition for improving brain function |
| KR101096528B1 (en) * | 2003-04-17 | 2011-12-20 | 토야마 케미칼 컴퍼니 리미티드 | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| RU2397169C2 (en) * | 2005-03-28 | 2010-08-20 | Тояма Кемикал Ко., Лтд. | Method for preparing 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)azetidine-3-ol or its salts |
| AU2006229271B2 (en) | 2005-03-28 | 2012-02-09 | Toyama Chemical Co., Ltd. | Process for production of 1-(3-(2-(1-benzothiophen-5-YL)- ethoxy)propyl)azetidin-3-ol or salts thereof |
| US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| KR101374593B1 (en) | 2006-04-26 | 2014-03-17 | 토야마 케미칼 컴퍼니 리미티드 | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| PL3100725T3 (en) * | 2014-01-31 | 2020-11-16 | Fujifilm Toyama Chemical Co., Ltd. | Post nerve injury rehabilitation effect-enhancing agent comprising an alkyl ether derivative or a salt thereof |
-
2015
- 2015-01-30 PL PL15743367T patent/PL3100725T3/en unknown
- 2015-01-30 SG SG11201606173TA patent/SG11201606173TA/en unknown
- 2015-01-30 SI SI201531278T patent/SI3100725T1/en unknown
- 2015-01-30 KR KR1020167023717A patent/KR102346219B1/en active IP Right Grant
- 2015-01-30 LT LTEP15743367.3T patent/LT3100725T/en unknown
- 2015-01-30 MY MYPI2016702668A patent/MY179290A/en unknown
- 2015-01-30 DK DK15743367.3T patent/DK3100725T3/en active
- 2015-01-30 RU RU2016135236A patent/RU2680247C2/en active
- 2015-01-30 SG SG10201907035TA patent/SG10201907035TA/en unknown
- 2015-01-30 JP JP2015539315A patent/JP5837726B1/en active Active
- 2015-01-30 BR BR112016017747A patent/BR112016017747A2/en not_active Application Discontinuation
- 2015-01-30 HU HUE15743367A patent/HUE050400T2/en unknown
- 2015-01-30 CN CN201580011450.3A patent/CN106061478B/en active Active
- 2015-01-30 WO PCT/JP2015/052617 patent/WO2015115582A1/en active Application Filing
- 2015-01-30 CA CA2938184A patent/CA2938184C/en active Active
- 2015-01-30 MX MX2016009751A patent/MX2016009751A/en active IP Right Grant
- 2015-01-30 AU AU2015211753A patent/AU2015211753B2/en active Active
- 2015-01-30 ES ES15743367T patent/ES2792950T3/en active Active
- 2015-01-30 PT PT157433673T patent/PT3100725T/en unknown
- 2015-01-30 EP EP15743367.3A patent/EP3100725B1/en active Active
- 2015-01-30 RS RS20200754A patent/RS60462B1/en unknown
- 2015-01-30 US US15/115,416 patent/US10039744B2/en active Active
- 2015-11-04 JP JP2015216722A patent/JP6642914B2/en active Active
-
2016
- 2016-07-25 IL IL24692516A patent/IL246925B/en active IP Right Grant
- 2016-07-29 PH PH12016501507A patent/PH12016501507A1/en unknown
- 2016-12-22 HK HK16114586A patent/HK1226298A1/en unknown
-
2018
- 2018-06-12 US US16/005,774 patent/US10471044B2/en active Active
-
2019
- 2019-12-26 JP JP2019236541A patent/JP6825074B2/en active Active
-
2020
- 2020-05-15 HR HRP20200796TT patent/HRP20200796T1/en unknown
- 2020-07-23 CY CY20201100673T patent/CY1123154T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1226298A1 (en) | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof | |
| GB201809461D0 (en) | Leg movement stimulator device | |
| IL250685A0 (en) | Cytotoxicity-inducing therapeutic agent | |
| ZA201607866B (en) | Solid-stabilized emulsion | |
| DK3233221T3 (en) | Training Facilities | |
| DK3107563T3 (en) | GLYCOM TARGETED THERAPEUTIC AGENTS | |
| GB201410816D0 (en) | Therapeutic agents | |
| IL250990A0 (en) | Human therapeutic agents | |
| GB2602935B (en) | Human lymphoid tissue-on-chip | |
| IL249356B (en) | 2-acylaminothiazole derivative or salt thereof | |
| GB201410815D0 (en) | Therapeutic agents | |
| GB201410817D0 (en) | Therapeutic agents | |
| PL3018257T3 (en) | Guardrail post | |
| GB201608979D0 (en) | Intraosseous infusion training system | |
| GB2526178B (en) | Horse-riding training device | |
| PL3085227T3 (en) | Movement trainer for small animals | |
| GB2532578B (en) | Animal amusement device | |
| KR101865628B9 (en) | Vertical Hanging Vegetation Device | |
| GB201402820D0 (en) | Fence attachment device | |
| GB2546148B (en) | Animal deterrent | |
| GB201415801D0 (en) | Cat Fight Deterrent Colar | |
| GB201421879D0 (en) | Therapeutic agents | |
| GB201421715D0 (en) | Therapeutic agents | |
| GB201409241D0 (en) | Therapeutic agents | |
| GB201409244D0 (en) | Therapeutic agents |